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Abstract 
 
The 14C and 13C labelled urea breath tests (UBT) for detecting Helicobacter 
pylori infection are well established but scope for improvement exists in both 
to reduce some of their shortcomings. 
 
For this study, the 14C UBT investigation focussed on reducing the quantity of 
radioactive tracer that is administered to the subject undergoing this test, 
with the aim of lowering the radiation dose to the patient, reducing the 
impact to the environment and exempting the test from radioactive materials 
licensing.  Wider acceptance, availability, affordability to lower socio-
economic groups and third party medical treatment payers and using readily 
available equipment were factors considered when developing the method. 
 
The principle of the method developed is to collect larger volume breath 
sample, quantitatively absorbing a defined volume of extracted breath CO2 in 
an efficient CO2 trapping agent using a specifically designed apparatus and 
measuring the activity with a low background β-spectrometer. 
 A reduction in the quantity of 14C labelled urea administered to the patient 
was achieved.  The method also reduced the counting error margin at a lower 
detection limit, improving discrimination between H. pylori positive and 
negative patients. 
The 13C UBT is a non-radioactive test however, it is substantially more 
expensive.  The 13C UBT investigation aimed to determine whether 
commercially available un-enriched urea could be used thus reducing the 
cost of the 13C UBT. 
 
A simple protocol with Isotope Ratio Mass Spectrometry (IRMS) for the 
measurement was used as opposed to the well-established 13C UBT protocol.  
The principle of the 13C UBT investigation was to detect the change of the 
breath δ13C (13C/12C) ratio after the administration of un-enriched urea with a 
δ13C different to the exhaled breath.  Theoretical calculations showed that an 
administered dose of 500mg un-enriched urea with at least a 10‰ δ13C 
difference may be detectable using IRMS. 
 
In vitro investigations confirmed that levels of 0.01 to 0.001‰ δ13C were 
detectable by IRMS.  A change in the δ13C of a standard breath CO2 was 
confirmed for a range between 0.14 to 50% v/v mixed CO2 samples, i.e. the 
projected range for in-vivo investigation.  Results from the in-vivo 
investigation however were not able to distinguish positive from negative H. 
pylori patients.  The use of the 1000mg dose of urea appears to have caused 
saturation of the enzyme.  It was concluded that some enrichment of the 13C 
is necessary or less urea be used. 
